Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

被引：7

作者：

Procopio, Giuseppe ^{[1
]}

Bamias, Aristotelis ^{[2
]}

Schmidinger, Manuela ^{[3
]}

Hawkins, Robert ^{[4
]}

Rodriguez Sanchez, Angel ^{[5
]}

Vazquez Estevez, Sergio ^{[6
]}

Srihari, Narayanan ^{[7
]}

Kalofonos, Haralabos ^{[8
]}

Bono, Petri ^{[9
]}

Babanrao, Chaitali ^{[10
]}

Hirschberg, Yulia ^{[11
]}

Dezzani, Luca ^{[11
]}

Ahmad, Qasim ^{[11
]}

Suarez Rodriguez, Cristina ^{[12
,13
]}

Jonasch, Eric ^{[14
]}

机构：

[1] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Via Venezian 1, I-20133 Milan, Italy

[2] Univ Athens, Dept Clin Therapeut, Alexandra Hosp, Athens, Greece

[3] Med Univ Vienna, Dept Med, Vienna, Austria

[4] Christie NHS Fdn Trust, Christie CRC Res Ctr, Manchester, Lancs, England

[5] Univ Hosp Leon, Campus Vegazana, Leon, Spain

[6] Hosp Univ Lucus Augusti, Dept Oncol, Lugo, Spain

[7] Shrewsbury & Telford Hosp NHS Trust, Dept Oncol, Shrewsbury, Salop, England

[8] Univ Patras, Dept Med, Div Oncol, Patras, Greece

[9] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[10] Novartis Healthcare Private Ltd, Hyderabad, India

[11] Novanis Pharmaceut Corp, E Hanover, NJ USA

[12] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain

[13] Univ Autonoma Barcelona, Ctr Cellex, Inst Oncol, Barcelona, Spain

[14] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

来源：

CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 03期

关键词：

Intermediate risk; Pazopanib; Prognosis; Renal cell carcinoma; SUNITINIB; THERAPY;

D O I：

10.1016/j.clgc.2019.01.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with intermediate-risk advanced renal cell carcinoma are a heterogeneous population, having either 1 or 2 risk factors. It is unclear whether all patients in this risk category should be treated similarly. A secondary analysis of the PRINCIPAL study of pazopanib found that patients can be stratified by number of risk factors and Eastern Cooperative Oncology Group performance status to more accurately predict outcomes. Introduction: The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). Patients and Methods: Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediate-risk International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Assessments included progression-free survival, overall survival, objective response rate, and safety. We also evaluated effectiveness based on number of risk factors, age, and performance status (PS), as well as safety in older and younger patients. Results: Three hundred sixty three and 343 intermediate-risk MSKCC and IMDC patients were included, respectively. The median progression-free survival was 13.8 months (95% confidence interval [CI], 10.7-18.1 months) and 7.4 months (95% CI, 6.2-10.3 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 13.1 months (95% CI, 10.7-18.1 months) and 8.1 months (95% CI, 6.4-10.7 months) for patients with 1 and 2 IMDC risk factors, respectively. The median overall survival was not reached and was 15.2 months (95% CI, 12.3-26.5 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 33.9 months (95% CI, 33.9 months to not estimable) and 19.4 months (95% CI, 14.3 months to not estimable) with 1 and 2 IMDC risk factors, respectively. A lower overall response rate was observed with Eastern Cooperative Oncology Group PS >= 2 (vs. PS < 2). All-grade treatment-related adverse events occurred in approximately 63% of patients, and the safety profile among older and younger patients was similar. Conclusions: Outcomes with pazopanib in intermediate-risk patients suggest that patients can be further stratified by number of risk factors (1 vs. 2) and Eastern Cooperative Oncology Group PS (< 2 vs. >= 2) to more accurately predict outcomes. (C) 2019 Published by Elsevier Inc.

引用

页码：E526 / E533

页数：8